Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Lluch

Showing results (1-10 of 186) with videos related to

Pageof 19
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 29, 2012
Evolution of tumour biology upon progression. Do we know our enemy?Ana Lluch, Ana Bosch
Medicina Clinica|March 11, 2006
[Neoadjuvant therapy for operable breast-cancer]Amelia Insa, Isabel Chirivella, Ana Lluch
Expert Opinion on Emerging Drugs|May 17, 2014
Emerging EGFR antagonists for breast cancerAna Lluch, Pilar Eroles, Jose-Alejandro Perez-Fidalgo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2020
Reply to Y. Usui et alAna Lluch, Carlos H Barrios, Laura Torrecillas, et al.
International Journal of Molecular Sciences|August 13, 2016
The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast CancerPaula Cabello, Begoña Pineda, Eduardo Tormo, et al.
Current Drug Targets|February 20, 2015
MicroRNAs in Breast Cancer: One More Turn in RegulationPilar Eroles, Eduardo Tormo, Begoña Pineda, et al.
Cancer Treatment Reviews|December 20, 2011
Molecular biology in breast cancer: intrinsic subtypes and signaling pathwaysPilar Eroles, Ana Bosch, J Alejandro Pérez-Fidalgo, et al.
Cancer Treatment Reviews|January 12, 2010
Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of researchAna Bosch, Pilar Eroles, Rosa Zaragoza, et al.
Cancer Treatment Reviews|May 11, 2013
Trastuzumab in small tumours and in elderly womenJoan Albanell, Eva M Ciruelos, Ana Lluch, et al.
Molecular and Cellular Biochemistry|May 30, 2013
Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survivalPatricia Rodrigues, Jessica Furriol, Eduardo Tormo, et al.
Pageof 19

Showing results (1-10 of 186) with videos related to

Sort By:
Pageof 19
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 29, 2012
Evolution of tumour biology upon progression. Do we know our enemy?Ana Lluch, Ana Bosch
Medicina Clinica|March 11, 2006
[Neoadjuvant therapy for operable breast-cancer]Amelia Insa, Isabel Chirivella, Ana Lluch
Expert Opinion on Emerging Drugs|May 17, 2014
Emerging EGFR antagonists for breast cancerAna Lluch, Pilar Eroles, Jose-Alejandro Perez-Fidalgo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2020
Reply to Y. Usui et alAna Lluch, Carlos H Barrios, Laura Torrecillas, et al.
International Journal of Molecular Sciences|August 13, 2016
The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast CancerPaula Cabello, Begoña Pineda, Eduardo Tormo, et al.
Current Drug Targets|February 20, 2015
MicroRNAs in Breast Cancer: One More Turn in RegulationPilar Eroles, Eduardo Tormo, Begoña Pineda, et al.
Cancer Treatment Reviews|December 20, 2011
Molecular biology in breast cancer: intrinsic subtypes and signaling pathwaysPilar Eroles, Ana Bosch, J Alejandro Pérez-Fidalgo, et al.
Cancer Treatment Reviews|January 12, 2010
Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of researchAna Bosch, Pilar Eroles, Rosa Zaragoza, et al.
Cancer Treatment Reviews|May 11, 2013
Trastuzumab in small tumours and in elderly womenJoan Albanell, Eva M Ciruelos, Ana Lluch, et al.
Molecular and Cellular Biochemistry|May 30, 2013
Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survivalPatricia Rodrigues, Jessica Furriol, Eduardo Tormo, et al.
Pageof 19